Roivant Sciences Ltd
NASDAQ:ROIV

Watchlist Manager
Roivant Sciences Ltd Logo
Roivant Sciences Ltd
NASDAQ:ROIV
Watchlist
Price: 21.71 USD -1.41% Market Closed
Market Cap: $15.1B

Net Margin

-1 839.6%
Current
Declining
by 3 157%
vs 3-y average of 1 317.4%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-1 839.6%
=
Net Income
$-374m
/
Revenue
$20.3m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-1 839.6%
=
Net Income
$-374m
/
Revenue
$20.3m

Peer Comparison

Country Company Market Cap Net
Margin
BM
Roivant Sciences Ltd
NASDAQ:ROIV
15B USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
978.7B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
547.3B USD
Loading...
CH
Roche Holding AG
SIX:ROG
277.3B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
210B GBP
Loading...
CH
Novartis AG
SIX:NOVN
220.8B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
273B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
150.2B USD
Loading...
FR
Sanofi SA
PAR:SAN
95.7B EUR
Loading...

Market Distribution

Lower than 98% of companies in Bermuda
Percentile
2st
Based on 196 companies
2st percentile
-1 839.6%
Low
-95 355.3% — 0.2%
Typical Range
0.2% — 8.3%
High
8.3% — 63.2%
Distribution Statistics
Bermuda
Min -95 355.3%
30th Percentile 0.2%
Median 2.1%
70th Percentile 8.3%
Max 63.2%

Roivant Sciences Ltd
Glance View

Market Cap
15.1B USD
Industry
Pharmaceuticals

Roivant Sciences Ltd. emerged as an intriguing figure in the pharmaceutical landscape, founded by the charismatic and driven Vivek Ramaswamy. The company operates like a strategic mosaic in the biotech industry, acquiring and developing promising drug candidates through a distinctive model that emphasizes speed and efficiency. At the heart of Roivant's strategy are its "Vants"—subsidiary companies that each focus on developing a specific type of therapeutic drug. This compartmentalized approach allows Roivant to cultivate multiple drug development streams simultaneously, mitigating risk while maximizing potential returns. By acquiring undervalued or overlooked drugs from larger pharmaceutical companies and advancing them through clinical trials, Roivant creates a robust pipeline of therapies ready to address unmet medical needs. Roivant generates revenue through the monetization of these therapies, either by bringing them to market directly or through strategic partnerships and licensing deals with larger pharmaceutical companies. By advancing drugs to critical points in clinical development, the company enhances their value significantly before either monetizing through commercialization or strategic exits like IPOs or partnerships. This business model creates a strong position in the drug development value chain, allowing Roivant to capture returns on its investments with focused precision. Additionally, Roivant brings an innovative twist to biotech investing by leveraging data analytics and technology to guide its decisions, aiming to streamline the traditionally costly and time-consuming drug development process. Beyond the financials, this approach paints Roivant as not just a player in biopharma but as an architect reshaping how medical innovations can reach patients more efficiently.

ROIV Intrinsic Value
2.92 USD
Overvaluation 87%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-1 839.6%
=
Net Income
$-374m
/
Revenue
$20.3m
What is Roivant Sciences Ltd's current Net Margin?

The current Net Margin for Roivant Sciences Ltd is -1 839.6%, which is below its 3-year median of 1 317.4%.

How has Net Margin changed over time?

Over the last 3 years, Roivant Sciences Ltd’s Net Margin has increased from -2 336.8% to -1 839.6%. During this period, it reached a low of -2 888.4% on Dec 31, 2022 and a high of 13 294.2% on Mar 31, 2024.

Back to Top